Aussie cannabis companies find footholds in the UK

Aussie cannabis companies find footholds in the UK

Two major cannabis companies Bod Australia (ASX: BDA) and Elixinol (ASX: EXL) have announced partnerships establishing relationships in the United Kingdom.

With a growing medicinal cannabis market estimated to be worth $14 billion by 2028, the UK is fast becoming an essential market for expanding companies.

Bod has signed an agreement with UK medicine manufacturer PCCA to import and distribute Bod's medicinal cannabis product MediCabilis throughout the UK.

The importing process is already underway, and Bod expects to receive first prescriptions in the UK in the coming months.

The group is witnessing "considerable" growth in patient numbers back in Australia and expects its expansion into the UK to bolster that revenue profile further.

As part of the agreement, Bod will also access PCCA's network of medical specialists and physicians through its medicinal cannabis education program.

Elixinol Global also has its sights set on the UK with its partnership with PharmaCare's Natrutopathica brand to create a co-branded CBD capsule range to be sold via Holland & Barret, a health and wellness retailer in the UK.

Naturopathica CBD+ encompasses six capsule-based products that blend Elixinol's CBD with specific vitamins and minerals to target different areas of health and wellbeing.

The range is the first CBD product to appear in prime-time television advertising, running on the UK's Channel 4 and ITV networks.

The product will be sold in Holland & Barret's online store as well as over 800 physical retail stores.

The two companies are following in the footsteps of Althea which received its first patient prescriptions in the UK for medicinal cannabis in June 2019.

The UK is Althea's second distribution channel for its current and future medicinal cannabis product, manufactured in Australia.

In other cannabis news, Cann Group (ASX: CAN) announced on Friday that the office of drug control had approved manufacturing licences for its existing northern and southern medicinal cannabis facilities in Melbourne.

The licences relate to the manufacturing, packaging, storage, transport and disposal of medicinal cannabis in final dose and intermediate forms.

The company now holds all cultivation, production and manufacture licenses under the Narcotics Drugs Act, along with import and export licences under the Customs Act.

Read more: Australia's top 20 cannabis companies

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

Enjoyed this article?

Don't miss out on the knowledge and insights to be gained from our daily news and features.

Subscribe today to unlock unlimited access to in-depth business coverage, expert analysis, and exclusive content across all devices.

Support independent journalism and stay informed with stories that matter to you.

Subscribe now and get 50% off your first year!

Four time-saving tips for automating your investment portfolio
Partner Content
In today's fast-paced investment landscape, time is a valuable commodity. Fortunately, w...
Etoro
Advertisement

Related Stories

REA Group buys full stake in end-to-end property sales interface Realtair

REA Group buys full stake in end-to-end property sales interface Realtair

Realestate.com.au operator REA Group (ASX: REA) has acquired the re...

HESTA to pump $250m into new global fund with Stafford Capital Partners

HESTA to pump $250m into new global fund with Stafford Capital Partners

Strong returns over the past three years from a $200 million global...

Breakthrough Victoria up to the test with $15m investment in Liquid Instruments

Breakthrough Victoria up to the test with $15m investment in Liquid Instruments

A Canberra-born, San Diego-headquartered technology company that re...

Pacific Smiles to extend nib dental offering to all centres

Pacific Smiles to extend nib dental offering to all centres

Takeover target Pacific Smiles (ASX: PSQ) may see its clinics filli...